Hard, not soft, plaque buildup may predict risk of heart attack
risk based monitoring :: Article Creator Cutting The Price Tag Of Clinical Trials With Risk-based Monitoring Rick Morrison Comprehend Systems In our R&,D innovation focus month, Rick Morrison presents the cost benefits to pharma associated with risk-based monitoring. On-site monitoring is a significant expense for pharmaceutical and biotech sponsors, accounting for up to 30 percent of the cost of a clinical trial. An extremely time-consuming and costly process, traditional site monitoring requires thousands of man hours that sponsors and CROs simply don't have to spare. A more centralized, risk-based approach can reduce the price tag of site monitoring and is actually more effective and safer for patients, because more focused data means better accuracy. In fact, the FDA has shifted its guidance over the last couple of years to encourage risk-based monitoring rather than full on-site monitoring. It's also been made possible by...